A study shows that combining dual immunotherapy with chemotherapy improves outcomes for metastatic non-squamous NSCLC patients with STK11 and KEAP1 mutations. Learn more ...

Researchers have discovered that combining immunotherapy and chemotherapy can overcome treatment resistance in a subset of ...

Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more ...

Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the ...

BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today preliminary safety data from ...

Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient ...

A severe solar storm is headed to Earth that could stress power grids even more as the US deals with disruptions from Hurricane Milton that hit Florida .

The trial entitled “Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway- Deficient NSCLC” is a Phase I/II trial where Phase I is a dose escalation study establishing the ...